erikoislääkkeitä

Erikoislääkkeitä are specialized medicines in Finland that are used to treat rare or severe diseases. These medicines are often highly innovative and are developed for conditions that affect a small number of people. Due to their complexity and specialized nature, their development, approval, and availability are subject to strict regulations.

The Finnish Medicines Agency (Fimea) plays a key role in the regulatory process for erikoislääkkeitä. This includes evaluating their safety, efficacy, and quality before they can be authorized for use. Once approved, the availability and reimbursement of these medicines are often managed through specific national systems designed to ensure access for patients who need them, while also considering the significant costs associated with their development and production.

The use of erikoislääkkeitä is typically restricted to hospitals or specialized healthcare units, and their administration is overseen by experienced medical professionals. This ensures that patients receive the appropriate treatment and monitoring. The high cost of these medicines means that their procurement and funding are a significant consideration for the Finnish healthcare system, often involving negotiations between manufacturers and national health authorities. The aim is to balance patient access with the sustainability of healthcare resources.